Anaconda Biomed is a Barcelona based medical device start-up co-founded by Dr. Marc Ribo and Dr. Ofir Arad. The company is developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies.


Stroke is the first cause of permanent disability in the world. The burden for the national health systems can be quantified in billions of dollars.


As numerous research has proven over the last few years, the best treatment in case of an Acute Ischemic Stroke is to perform a mechanical thrombectomy. Dr. Ribo’s research published on April 2015 on the New England Journal of Medicine* prove to be the stroke that broke the medical community camel’s back.

*Additional SourceNew England Journal of MedicineSource Reference: Furlan AJ "Endovascular therapy for stroke -- it's about time" N Engl J Med 2015; DOI: 10.1056/NEJMe1503217.


  • Area de Negocio
  • Dispositivos médicos
  • Cardiovascular y sistema circulatorio
  • Tipo de Empresa
  • Biotecnología sanitaria
Headquarter
Plaça Catalunya 1, 4th Floor
Barcelona , Barcelona 08002, ES
T: +34 930 484 314 or +34 636 332 859
E:info@anaconda.bio
Oficina
Camí de Ca N’Ametller 20
Sant Cugat del Vallés, Barcelona 08195 , ES
T: +34 930 484 314 or +34 636 332 859
E:info@anaconda.bio

The team is made of a group of professionals led by Dr. Ofir Arad with 15 years’ experience in the biomed industry and by Dr. Marc Ribó, a leading interventional neurologist practicing at Vall d’Hebron Hospital in Barcelona, one of the best hospitals in the world for Acute Ischemic Stroke treatment.


Dr. Marc Ribó - Interventional Neurologist
Alain Garcinuño - Consultant, Business Angel
Iñaki Galve - R&D director
Dr. Ofir Arad - Co-founder & CEO
Uri Fligil - Consultant
Our board of directors and scientific advisors include several national and international well known figures in the industry

The company is developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies.

Anaconda Biomed is focused on patients and its products have the aim of reducing intervention time, minimizing side effects, increasing clinical outcomes and saving more lives.

Anaconda BioMed